Background: Epilepsy is chronic neurological disorder characterized by recurrent unprovked seizure of cerebral origin with motor, sensory or autonomic disturbance with or without loss of consciousness. A wide spectrum of comorbid conditions either coexist at the time of presentation in a child with epilepsy or develop subsequently. These are often concern to the parents-at times even more than the seizures themselves as the seizures may be under controlled with AEDs. In children it is occassionaly associated with variable comorbidites although the frequency of such comorbidity is often difficult to determine. Many comorbidites associated with epilepsy are age dependent, earliar the insult of seizure, more damage to the growing brain. So, very early onset (<6months) seizure group showed more impairments that early onset group( >6months of age). Objectives: To identify neurodevelopmental comorbidites of children with epilepsy attending in child development center of ICMH. Methods: This cross sectional study was done from 8th March 2016 to 8th September 2016 at SCDDMC of ICMH. Detailed information were obtained in each cases according to protocol. Complete history was taken either from patient or accompying attendants. All epilepsy (15months to 15years) patient attending in Saleh child development & disability management center, had been follow- up there for at least 1year. Result: In this study, among the 175 children with epilepsy, Mean age of the studied children was 4.7(±2.8):age range 1- 2years.Male were 129(73.7%) and female were 46(26.3%),male female ratio was M:F-2.8:1.Demographic characteristics of epilepsy among studied cases showed that 27(15.4%) children came from low income group,129(73.7%) children came from middle income group,19(10.9%) came from high income group. In this study, 102(58.3%) patients had onset of seizure before 1months of age. Mean age of onset of seizure was found 9.9±21.4months. Majority 102(58.3%) patients had generalized clonic, .....

Background: Persistent pulmonary hypertension of the newborn (PPHN) is a serious disease among newborns. Pulmonary vasodilators such as Sildenafil, Bosentan and Milrinone are important treatment modalities to treat persistent pulmonary hypertension of the newborn, especially in resource limited centers where inhaled nitric oxide is not available. Objective: To assess and compare the effectiveness of Bosentan and Sildenafil in persistent pulmonary hypertension of the newborn. Method: This randomized controlled trial was done in the NICU, ICMH, Matuail, Dhaka during July 2017 to July 2019. Following echocardiographic diagnosis, a total of 76 patients were randomly assigned into group A and group B (by lottery). Bosentan was given to group A (1mg/kg/body wt) 12 hourly for 7 days and Sildenafil was given to group B (2mg/kg/body wt.) 8 hourly for 7 days via oro-gastric tube/orally. Then heart rate, respiratory rate, cyanotic changes, SPO2 was recorded every day for 7 days and finally on the 8th day echocardiographic findings were obtained. Effects of two groups were compared. Results: The age of presentation of persistent pulmonary hypertension of newborn was < 24 hours and male newborns were predominant in both groups. Almost 100 % newborns had cyanosis, tachypnea and SPO2 <80% on admission. After intervention for 7 days in both groups no newborn had cyanosis or tachypnea. The mean pulmonary artery systolic pressure (PASP) on echocardiography before and after intervention was found (53.16 ± 9.263 and 35.55 ± 6.41) mm of Hg in group A. The mean PASP on echocardiography before and after intervention was found (53.24 ±11.012 and 35.45 ± 7.43) mm of Hg respectively in group B. In both groups the mean PASP was decreased significantly after intervention. But while comparing the PASP between two groups, there was no significant (p>0.05) difference. The mean length of stay in hospital was 13.05 ± 2.96 days for group A and 13.34 ± 2.86 days for group B. The mean length of ......